Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities (2017 - 2025)

Northwest Biotherapeutics (NWBO) has 8 years of Preferred Stock Liabilities data on record, last reported at $13.4 million in Q3 2025.

  • For Q3 2025, Preferred Stock Liabilities fell 15.6% year-over-year to $13.4 million; the TTM value through Sep 2025 reached $13.4 million, down 15.6%, while the annual FY2024 figure was $15.5 million, 17.15% down from the prior year.
  • Preferred Stock Liabilities reached $13.4 million in Q3 2025 per NWBO's latest filing, down from $13.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $27.7 million in Q3 2023 and bottomed at $13.4 million in Q3 2025.
  • Average Preferred Stock Liabilities over 4 years is $18.8 million, with a median of $18.7 million recorded in 2023.
  • Peak YoY movement for Preferred Stock Liabilities: skyrocketed 101.27% in 2023, then plummeted 42.61% in 2024.
  • A 4-year view of Preferred Stock Liabilities shows it stood at $23.1 million in 2022, then fell by 18.83% to $18.7 million in 2023, then fell by 17.15% to $15.5 million in 2024, then dropped by 13.59% to $13.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Preferred Stock Liabilities were $13.4 million in Q3 2025, $13.8 million in Q2 2025, and $14.6 million in Q1 2025.